- Trials with a EudraCT protocol (732)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
732 result(s) found for: Lymphocyte.
Displaying page 7 of 37.
EudraCT Number: 2014-004015-36 | Sponsor Protocol Number: IN-IT-236-1320 | Start Date*: 2015-02-16 |
Sponsor Name:AZIENDA OSPEDALIERA SAN PAOLO | ||
Full Title: Role of a switch strategy to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (QUAD) on HIV reservoir and immune activation. | ||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005860-24 | Sponsor Protocol Number: OmniaOMS | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA | |||||||||||||
Full Title: Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis | |||||||||||||
Medical condition: relapsing remitting multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003021-18 | Sponsor Protocol Number: 109MS308 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis | |||||||||||||
Medical condition: Secondary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IT (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000637-41 | Sponsor Protocol Number: EFC16033 | Start Date*: 2020-07-31 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) CZ (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) LT (Completed) PL (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003032-22 | Sponsor Protocol Number: ALL-SCT-ped-FORUM | Start Date*: 2013-02-04 |
Sponsor Name:St. Anna Kinderkrebsforschung GmbH | ||
Full Title: Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia - FORUM | ||
Medical condition: acute lymphoblastic leukaemia | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) DE (Trial now transitioned) NO (Trial now transitioned) FI (Completed) DK (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016378-34 | Sponsor Protocol Number: MI-CP204 | Start Date*: 2010-06-30 | |||||||||||||||||||||
Sponsor Name:MedImmune LLC | |||||||||||||||||||||||
Full Title: An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies | |||||||||||||||||||||||
Medical condition: Relapsed or refractory advanced B-cell malignancies: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin’s lymphoma (NHL) (subtypes: follicular lymphoma (FL)... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003967-23 | Sponsor Protocol Number: PCYC-1115-CA | Start Date*: 2013-02-05 | |||||||||||
Sponsor Name:Pharmacyclics, Incorporated | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic L... | |||||||||||||
Medical condition: Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003253-21 | Sponsor Protocol Number: 2013-99 | Start Date*: 2018-05-30 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents | |||||||||||||
Medical condition: mature aggressive B-cell lymphoma and leukemia in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004680-39 | Sponsor Protocol Number: AUTO3-PA1 | Start Date*: 2017-06-21 | ||||||||||||||||
Sponsor Name:Autolus Limited | ||||||||||||||||||
Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Adult Patients with R... | ||||||||||||||||||
Medical condition: Acute lymphoblastic leukaemia (ALL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001113-14 | Sponsor Protocol Number: TEM-IIG-2 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Fundación Hospital Clinic i Provincial | |||||||||||||
Full Title: Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients | |||||||||||||
Medical condition: Renal Cell Carcinoma Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003086-40 | Sponsor Protocol Number: PIX001 | Start Date*: 2008-04-08 |
Sponsor Name:Fondation Charcot Stichting | ||
Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | ||
Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001749-42 | Sponsor Protocol Number: 484/12 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on lung inflammation in COPD. | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003689-28 | Sponsor Protocol Number: BrEPEM-LH-22017 | Start Date*: 2018-04-05 | |||||||||||
Sponsor Name:GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea) | |||||||||||||
Full Title: A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Ly... | |||||||||||||
Medical condition: Older Patients with Untreated Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001514-34 | Sponsor Protocol Number: ILNK15-01 | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study | |||||||||||||
Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021221-12 | Sponsor Protocol Number: UMC Utrecht | Start Date*: 2011-07-11 | |||||||||||
Sponsor Name:UMCU | |||||||||||||
Full Title: A phase I/ II study Efficacy and safety of alpha/beta T- /CD19B-cell depleted allogeneic haematopoietic stem cells transplantation in high risk or relapsed acute leukaemia / MDS followed by an inn... | |||||||||||||
Medical condition: Patients with high risk acute leukemia / MDS or relapse acute leukemia /MDS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020146-10 | Sponsor Protocol Number: LEG-SIL-LTX-02 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:ROTTAPHARM S.P.A. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LEGALON SIL FOR THE TREATMENT OF HCV RECURRENCE IN STABLE LIVER TRANSPLANTED PATIENTS. | |||||||||||||
Medical condition: HCV recurrence in stable liver transplanted patients not responding to treatment with peginterferon/ribavirin (i.e. the so called standard of care,SOC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001417-32 | Sponsor Protocol Number: 2018/070/HP | Start Date*: 2018-07-13 | |||||||||||
Sponsor Name:CHU-Hôpitaux de Rouen | |||||||||||||
Full Title: Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation | |||||||||||||
Medical condition: Patients with Bullous pemphigoid included in RITUXIMAB3 study | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004501-24 | Sponsor Protocol Number: CT-2011-01 | Start Date*: 2012-03-06 | |||||||||||
Sponsor Name:CureTech Ltd. | |||||||||||||
Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma | |||||||||||||
Medical condition: Metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006716-38 | Sponsor Protocol Number: 0816002 | Start Date*: 2009-05-11 | |||||||||||
Sponsor Name:CHU de Toulouse | |||||||||||||
Full Title: Etude observationnelle des évènements indésirables graves survenant chez les patients traités par rituximab pour maladie dysimmunitaire hors polyarthrite rhumatoïde . | |||||||||||||
Medical condition: maladies dysimmunitaires hors polyarthrite rhumatoîde | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006272-39 | Sponsor Protocol Number: DRV600 | Start Date*: 2012-04-26 | |||||||||||
Sponsor Name:Fundació Lluita contra la SIDA | |||||||||||||
Full Title: CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY AND ECONOMIC IMPACT OF REDUCING DOSES OF DARUNAVIR IN PATIENTS INFECTED WITH HIV TREATED WITH DARUNAVIR / RITONAVIR ONCE A DAY | |||||||||||||
Medical condition: HIV-infected patients on stable treatment with darunavir / ritonavir 800/100 mg qd plus two transcriptase inhibitors, nucleoside analogs for at least 4 weeks. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
